Corrective Phases R...
Health Care: Drugs
Cell Therapeutics Inc. (CTIC: NASDAQ)
$0.86 -0.03 | -3.86%
06/01/12 - 04:00 PM ET
Company Income Statement
| Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | |
| Sales | 0.00 | 319.00K | 80.00K | 11.43M |
| Cost of Sales | -2.41M | -1.84M | -1.77M | -326.00K |
| Gross Operating Profit | 2.41M | 2.16M | 1.85M | 11.76M |
| Selling, General, and Administrative Expenses | 38.29M | 48.04M | 57.72M | 41.61M |
| Research & Development | 34.90M | 27.03M | 30.18M | 51.61M |
| Operating Income before D & A (EBITDA) | -70.78M | -72.91M | -86.05M | -81.46M |
| Depreciation & Amortization | 2.41M | 1.84M | 1.77M | 5.23M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Income - Net | 11.61M | -5.75M | -8.08M | -84.75M |
| Special Income / Charges | 0.00 | 0.00 | 6.26M | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -61.58M | -80.50M | -90.84M | -171.60M |
| Interest Expense | 1.04M | 2.33M | 4.81M | 8.56M |
| Pre-Tax Income | -62.62M | -82.84M | -95.65M | -180.16M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | -259.00K | -194.00K | -252.00K | -126.00K |
| Net Income From Continuing Operations | -62.36M | -82.64M | -95.40M | -180.03M |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -62.36M | -82.64M | -95.40M | -180.03M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -62.36M | -82.64M | -95.40M | -180.03M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-62.36M | -82.64M | -101.66M | -179.99M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -121.08M | -147.56M | -116.76M | -202.91M |
| Basic EPS from Continuing Ops. | -0.71 | -1.32 | -1.50 | -42.00 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.71 | -1.32 | -1.50 | -42.00 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.71 | -1.32 | -1.50 | -42.00 |
| Basic Normalized Net Income/Share | -0.71 | -1.32 | -1.60 | -41.99 |
| EPS fr Continuing Ops. | -0.71 | -1.32 | -1.50 | -42.00 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.71 | -1.32 | -1.50 | -42.00 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.71 | -1.32 | -1.50 | -42.00 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-0.71 | -1.32 | -1.60 | -41.99 |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with CTIC
- Portfolio NameUser Type
- ContributorUnder-$10 Setting Up To Tra...
- User2012 stock
- ContributorCancer Drug Stocks to Trade...
- UserImagine!
- Userfrankiesun09@gmail.com
- UserASCO 2010
- Contributor10 Biotech Stocks Facing FD...
- Userbiotech121
- UserJswaim
- UserSLITraders
Latest CTIC Headlines from TheStreet
- Cell Therapeutics Juggles Chainsaws To Distract Investors From Its Dead-End Course 04.19.12 | 03:04 pm
- The 5 Dumbest Things on Wall Street This Week: Feb. 3 02.03.12 | 06:02 am
- The 5 Dumbest Things on Wall Street: Feb. 3
02.03.12 | 05:02 am - Cell Therapeutics Pulls Cancer Drug After CEO Boasted About Approval Chances 01.30.12 | 05:01 am
- Play TheStreet's FDA Drug-Approval Contest 01.23.12 | 08:01 am
- 5 Under-$10 Stocks Set to Soar 12.29.11 | 06:12 pm
- The Worst Biotech CEO of 2011 Is ... 12.09.11 | 07:12 am
- Biotech Stock Mailbag: Affymax 12.02.11 | 06:12 am
- 22 Hot Drugs Facing FDA Approval in 2012 11.29.11 | 08:11 am
- 10 Best Mutual Funds for 2012 11.16.11 | 07:11 am
Press Releases for CTIC
- Cell Therapeutics Completes Acquisition Of Pacritinib A Highly Selective JAK2 Inhibitor - PR Newswire 06.04.12 | 01:06 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 06.01.12 | 04:06 pm
- Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published In The Lancet Oncology - PR Newswire 05.31.12 | 01:05 am
- Cell Therapeutics' Aequus BioPharma Validates Its Proprietary GlycoPolymer Technology For The Extension Of The Half-life Of Therapeutic Protein Drugs - PR Newswire 05.30.12 | 01:05 am
- Cell Therapeutics To Host Investor And Analyst Meeting To Discuss Targeted Agents In Myelofibrosis And High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia On Sunday, June 3, 2012, In Chicago - PR Newswire 05.29.12 | 04:05 pm
- Cell Therapeutics Announces Institutional Investor To Purchase $40 Million Of Convertible Preferred Stock And Warrants To Purchase Common Stock - PR Newswire 05.29.12 | 03:05 am
- Cell Therapeutics' Pixuvri® Approved In European Union As Monotherapy To Treat Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas - PR Newswire 05.10.12 | 02:05 pm
- Cell Therapeutics Enters Into Agreement To Acquire Pacritinib, A Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate For Myelofibrosis - PR Newswire 04.19.12 | 01:04 am
- University Of Washington's Neuro-Oncology Program To Investigate Cell Therapeutics' Drug Candidate OPAXIO⢠(Paclitaxel Poliglumex) Plus Radiotherapy For Glioblastoma Multiforme, A Highly Malignant Brain Cancer - PR Newswire 03.27.12 | 01:03 am
- European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri⢠- PR Newswire 02.17.12 | 07:02 am
Partner Headlines for CTIC
- 5 Biotech Stocks That Could Double - Seeking Alpha 02.01.12 | 07:02 am
- Cell Therapeutics Plummeting on NDA Withdrawl - Benzinga 01.30.12 | 09:01 am
- US Panel to Review CTIC's Pixantrone - Analyst Blog - Zacks 01.04.12 | 10:01 am
- Mid-Day Update: Stocks Higher; Investors Cheer European Fiscal Deal - NASDAQ 12.09.11 | 05:12 pm
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Zacks #1 Rank Additions for Friday - Tale of the Tape - Zacks 11.11.11 | 09:11 am
- CTIC Loss Widens, Resubmits NDA - Analyst Blog - Zacks 10.27.11 | 10:10 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Cell Therapeutics Efforts Validated - Analyst Blog - Zacks 10.07.11 | 04:10 pm
- Morning Market Movers - Benzinga 08.31.11 | 09:08 am
